Catasyn™ Hydrogel + SynePure™ Cleanser and Silver Sulfadiazine for Superficial Burns
Trial Summary
What is the purpose of this trial?
This trial tests a special wound cleaning solution and healing gel on adults with minor burns. The cleanser helps clean the burn, and the gel keeps it moist to improve healing.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It is best to discuss this with the trial coordinators or your doctor.
What data supports the effectiveness of the treatment Catasyn™ Hydrogel + SynePure™ Cleanser and Silver Sulfadiazine for superficial burns?
Research shows that hydrogels and silver sulfadiazine are effective in reducing pain and preventing bacterial contamination in burn wounds. A study found that hydrogels can provide better pain relief compared to silver sulfadiazine alone, and another study highlighted the antibacterial benefits of silver sulfadiazine when used in a hydrogel form.12345
Is the combination of Catasyn™ Hydrogel, SynePure™ Cleanser, and Silver Sulfadiazine safe for treating superficial burns?
Silver sulfadiazine is commonly used for burn wounds due to its antibacterial properties, but it can cause inflammation and cell toxicity. Studies have explored combining it with hydrogels to improve safety and effectiveness, suggesting that these combinations may be safer than using silver sulfadiazine alone.12356
How does the Catasyn™ Hydrogel + SynePure™ Cleanser and Silver Sulfadiazine treatment differ from other burn treatments?
This treatment is unique because it combines Catasyn™ Advanced Technology Hydrogel and SynePure™ Wound Cleanser with silver sulfadiazine, which is known for its antibacterial properties. The hydrogel component may help in reducing pain and improving healing by keeping the wound moist, while the silver sulfadiazine provides broad-spectrum antibacterial protection, potentially enhancing the overall effectiveness compared to using silver sulfadiazine alone.12347
Research Team
J. Peter Rubin, MD
Principal Investigator
University of Pittsburgh
Eligibility Criteria
Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive either SynePure Wound Cleanser and Catasyn Advanced Technology Hydrogel or Silvadene for up to 21 days
Follow-up
Participants are monitored for safety and effectiveness after treatment, including scar assessment and infection rate
Treatment Details
Interventions
- Catasyn™ Advanced Technology Hydrogel and SynePure™ Wound Cleanser
- Silver Sulfadiazine
Find a Clinic Near You
Who Is Running the Clinical Trial?
J. Peter Rubin, MD
Lead Sponsor
United States Department of Defense
Collaborator
Synedgen, Inc.
Industry Sponsor
Synedgen, Inc
Collaborator